Plasma Aβ40 and Aβ42 and Alzheimer's disease

Relation to age, mortality, and risk

R. Mayeux, MD; L.S. Honig, MD; M.-X. Tang, PhD; J. Manly, PhD; Y. Stern, PhD; N. Schupf, PhD; and P.D. Mehta, PhD

Abstract—*Background:* Plasma amyloid β-peptide (Aβ) 40 and Aβ42 levels are increased in persons with mutations causing early-onset familial Alzheimer's disease (AD). Plasma Aβ42 levels were also used to link microsatellite genetic markers to a putative AD genetic locus on chromosome 10 and were observed in patients with incipient sporadic AD. *Methods:* The authors measured plasma Aβ40 and Aβ42 levels using a sandwich ELISA after the initial examination of 530 individuals participating in an epidemiologic study of aging and dementia. Participants were examined at 18-month intervals, and plasma Aβ40 and Aβ42 levels were repeated in 307 subjects 3 years after baseline. *Results:* Compared with individuals who never developed AD, patients with AD at baseline and those who developed AD during the follow-up had significantly higher Aβ42, but not Aβ40, plasma levels. The risk of AD in the highest quartile of plasma Aβ42 was increased by more than twofold over that in the lowest quartile. The highest plasma Aβ42 levels were observed in patients with AD who died during the follow-up. Plasma Aβ42, but not Aβ40, levels decreased over time in patients with newly acquired AD. *Conclusions:* Plasma Aβ40 and Aβ42 increase with age and are strongly correlated with each other. Plasma Aβ40 and Aβ42 levels are elevated in some patients before and during the early stages of AD but decline thereafter. High plasma Aβ42 levels may also be associated with mortality in patients with AD.

NEUROLOGY 2003;61:1185–1190

Amyloid β-peptide (Aβ) peptide deposition in the brain and blood vessels is a distinctive manifestation of Alzheimer's disease (AD).[1] Two peptides of 40 and 42 amino acids in length (Aβ40 and Aβ42) are derived from the larger β-amyloid precursor protein (βAPP), which is expressed throughout the body. The Aβ peptides have also been detected in CSF, urine, plasma, and skin.[2-7] Aβ42 is increased in the plasma of affected and unaffected family members with mutations in presenilin 1 and 2 and the APP that cause early-onset familial AD.[8] Plasma Aβ40 and Aβ42 levels represent a heritable trait that has been used in a linkage analysis of chromosome 10 to AD, suggesting that variant forms of a gene may be associated with elevated levels of Aβ42.[9,10] The source of Aβ40 and Aβ42 in plasma is unknown, however. The brain has been considered the origin of deposited Aβ in the brain of patients with AD, but peripheral sources such as blood may also be important.[11]

Compared with age-matched control subjects, Aβ40 and Aβ42 levels are significantly increased in the plasma of patients with Down syndrome and further increased in the presence of dementia or the ε4 variant of *APOE*.[12] We previously reported an increase in plasma Aβ42 among individuals with incipient AD in a previous study.[6] Our results suggested that plasma Aβ42 might be a biological risk factor for AD but was not useful as a diagnostic test. The current study was designed to extend the risk analysis of plasma Aβ42 levels with incident AD and to determine whether plasma Aβ42 levels change with disease progression, age, or other characteristics.

Methods. *Study population.* Plasma Aβ40 and Aβ42 and clinical data were obtained from 530 individuals randomly selected from 2,126 Medicare recipients, 65 years and older, residing in northern Manhattan in New York City and participating in a study of aging and dementia. The sampling procedures for the parent study have been described elsewhere.[13] Participants underwent an in-person structured interview of health, a physical and neurologic examination, and a neuropsychological battery at the time of study entry, which was repeated at approximately 18-month intervals. Only individuals who completed at least one follow-up were included in the analyses. The Columbia University Institutional Review Board reviewed and approved this project. All individuals provided written informed consent.

Clinical assessments. Physicians completed standardized medical and neurologic histories and examinations. With use of a standard protocol, standing body weight to the nearest 0.1 kg with a balance scale (Scale-Tronix, Wheaton, IL) and height without shoes to nearest 0.5 cm were measured using a stadiometer (GNP,

Geneva, Switzerland) to calculate body mass index (BMI = weight/height^2).

The neuropsychological test battery, previously validated for this geographic area,[14,15] was given in either Spanish or English. The battery consisted of the orientation subtest from the modified Mini-Mental State Examination,[16] the Boston Naming Test,[17] the Controlled Word Association Test,[18] category naming, the Complex Ideational Material and Phrase Repetition Subtests of the Boston Diagnostic Aphasia Evaluation,[19] the Abstract Reasoning and Similarities Subtests from the Wechsler Adult Intelligence Scale–Revised,[20] the nonverbal Identities and Oddities Subtest of the Mattis Dementia Rating Scale,[21] the Rosen Drawing Test,[22] the matching version and the multiple-choice version of the Benton Visual Retention Test,[23] and the Selective Reminding Test.[24]

After each clinical assessment, a group of physicians and neuropsychologists reviewed the data and reached a consensus regarding the presence or absence of dementia[25] using published criteria for probable and possible AD.[26] Severity of AD was rated using the Clinical Dementia Rating Scale (CDR).[27] The consensus group was shielded from the plasma Aβ levels.

Ethnic group. At baseline, ethnic group was documented by self-report using the format of the 1990 US Census.[28] All individuals were first asked to indicate their racial group and then whether or not they were of "Hispanic origin."

Plasma lipids. Fasting plasma total cholesterol and triglyceride levels had also been determined from plasma ascertained at baseline using standard enzymatic techniques. High-density lipoprotein (HDL) cholesterol was determined after precipitation of ApoB-containing lipoproteins with phosphotungstic acid. Low-density lipoprotein cholesterol levels were calculated using the formula of Friedewald et al.[29] This was done to examine the putative relation between alterations in cholesterol and Aβ levels in AD.[30]

APOE *genotype.* Genotypes were obtained by amplification of genomic DNA with PCR subjected to *Cfo*I restriction analysis using *APOE* primers and conditions similar to those described by Hixson and Vernier[31] and modified by Maestre et al.[32]

Plasma Aβ40 and Aβ42. Plasma obtained at baseline and follow-up was stored within 2 hours after collection at −70 °C. Aβ40 and Aβ42 levels were measured using a combination of monoclonal antibody 6E10 (specific to an epitope present on 1 to 16 amino acid residues of Aβ) and rabbit antibodies specific for Aβ40 (R162) and Aβ42 (R165) in a double-antibody sandwich ELISA.[33,34] The detection limit for this assay was 5 pg/mL for Aβ40 and 10 pg/mL for Aβ42. Previously, we had established that the test–retest reliability of the measurement of plasma Aβ40 and Aβ42 was excellent (Cronbach's α coefficient = 0.91).[6]

Data analysis. Continuous measures were compared across groups using Student's *t*-test, and categorical variables were compared using the χ^2 test. We subtracted the value of the plasma Aβ levels at baseline from that acquired 3 years later to estimate the change in levels over time. The change was compared using analysis of variance. Correlations between variables were completed using Pearson's correlation coefficient. Log transformation was used for continuous variables that appeared skewed. Univariate regression models were used to determine the relation between AD and plasma Aβ levels, and multivariate regression models were used to adjust for potential confounders. Finally, we used Cox regression to examine the rate ratio for AD associated with plasma Aβ42 levels divided into quartiles, in which the lowest quartile was used as the reference. For these analyses, we used duration of follow-up from the baseline measurement of plasma Aβ levels as the time-to-event variable. In subsequent analyses, we adjusted for age, education, *APOE* genotype, and BMI. All analyses were conducted using SPSS for Windows (version 10.1.3; Chicago, IL).

Results. At the baseline assessment, there were 79 (14.9%) patients with clinically diagnosed AD (CDR ≥ 1.0) among the 530 individuals in the study. The remaining 451 individuals were free of dementia (400 were CDR = 0 and 51 CDR = 0.5). Over the subsequent 5 years, 65 (16.3%) of the 400 without dementia and 21 (41.2%) of those with mild impairment (CDR = 0.5) developed AD (CDR = 1).

Compared with those who remained healthy, there were more African Americans and Hispanics than whites and more women than men with AD at baseline (table 1). Patients with AD were also older, less well educated, and more likely to have an *APOE-ε4* allele than those without dementia. Over the follow-up period, more African Americans and Hispanics than whites and more women than men developed AD (see table 1). Individuals who developed AD were more likely to be older, less well educated, and more likely to have an *APOE-ε4* allele than those who remained free of dementia. BMI was lower among the patients with AD at baseline than among newly diagnosed patients with AD or control subjects (see table 1).

Plasma Aβ40 and Aβ42 levels were correlated ($r = 0.22$, $p = 0.001$), and both increased with age (Aβ40 $r = 0.23$, $p < 0.001$; Aβ42 $r = 0.15$, $p < 0.001$). Aβ40, but not Aβ42, levels were inversely related to serum cholesterol and HDL levels ($r = -0.12$, $p = 0.005$, for both). Aβ42, but not Aβ40, level was inversely related to BMI ($r = -0.1$, $p = 0.05$). Neither Aβ40 nor Aβ42 levels differed by the presence or absence of an *APOE-ε4* allele.

The initial Aβ40 and Aβ42 levels differed significantly in those individuals with AD at baseline compared with those without dementia (see table 1). More importantly, Aβ40 and Aβ42 levels were significantly higher in those who subsequently developed AD over the follow-up period (see table 1). The baseline Aβ40 levels, but not the Aβ42 levels, differed between those with CDR = 0 and those with CDR = 0.5 (Aβ40 131.5 [52.8; SD] vs 152.6 [94.8] pg/mL, $p = 0.05$; and Aβ42 61.3 [40.8] vs 69.5 [31.9] pg/mL, $p = 0.2$). However, regardless of the initial CDR, those who subsequently developed AD had higher baseline Aβ42 than those who never developed AD (Aβ42 CDR 0 = 77.4 [66.5], CDR 0.5 = 73.8 [31.9] vs controls 58.8 [32.9]; F = 14.1, $p = 0.0001$).

Because the distributions of Aβ40 and Aβ42 levels were skewed, the comparison was repeated using log transformations of Aβ40 and Aβ42 levels, and all of the associations with newly acquired AD described above remained significant. However, with multivariate analysis of covariance adjusting for age, BMI, and Aβ40 level, only Aβ42 levels remained significantly different when comparing those who never developed AD with those who developed AD over the follow-up period. In contrast, there were no significant differences in the Aβ40 level across the groups in the adjusted analysis. We also found no differences in the plasma Aβ40 and Aβ42 levels by disease severity using either the first or the last CDR rating. However, only two individuals had CDR ratings that exceeded 2, which reflects the fact that most patients had only mild disease.

Compared with the lowest quartile of plasma Aβ42 level at baseline, the unadjusted rate ratio for AD was significantly increased for each successive quartile after the second quartile (table 2). This association did not change in a multivariate Cox regression model that included Aβ40 level, age, BMI, education, and *APOE-ε4*. The figure shows the cumulative proportion of affected individuals within each quartile of plasma Aβ42. Only the upper two quartiles differed significantly from the lowest quartile, though the risk did increase for each quartile.

The baseline Aβ42 plasma level was also consistently and significantly higher among those individuals who developed AD at any time point during the follow-up than among those who never developed AD after 5 years of

Table 1 *Baseline demographics by final diagnoses*

Demographics, n = 530	AD at baseline	AD at follow-up	Nondemented elderly*
No. (%)	79 (14.9)	86 (16.2)	365 (68.9)
Mean (SD) age,†	83.2 (7.9)	79.3 (6.6)	75.5 (5.9)
Mean (SD) education,†	6.4 (4.2)	6.8 (4.5)	9.0 (4.6)
Gender,‡ women %	86.1	79.1	66.6
African American, %	15.7	16.8	67.5
Caribbean Hispanic, %	17.5	19.7	62.8
White, %	6.6	7.6	85.8
APOE-ε4 present,§ %	39.2	32.1	26.7
BMI (SD)§	25.7 (4.9)	27.4 (6.2)	27.5 (5.8)
Mean (SD) cholesterol, mg/dL	198.1 (42.3)	196.0 (41.4)	201.2 (40.8)
Mean (SD) Aβ40,§‖ pg/mL	153.6 (46.7)	136.2 (46.7)	133.3 (61.9)
Mean (SD) Aβ42,†§¶ pg/mL	68.7 (24.2)	76.5 (59.8)	58.8 (32.9)
Mean (SD) Aβ42/Aβ40*§	0.49 (0.23)	0.61 (0.53)	0.48 (0.3)

Note that for ethnic groups, the percentages reflect within-group proportions. African Americans do not include Hispanics. Hispanics are exclusively from the Caribbean Islands and Central and South America. Whites are of Eurasian ancestry and not Hispanic.

*Individuals who remained free of dementia throughout the follow-up period.
†$P < 0.001$.
‡$P < 0.01$.
§$P < 0.05$.
‖Linear trend, $P < 0.05$.
¶Linear trend, $P < 0.001$.

AD = Alzheimer's disease; BMI = body mass index; λAβ = amyloid β-peptide.

follow-up (mean Aβ42 levels for controls over the entire period 58.8 pg/mL, AD after 2 years of follow-up 77.1 pg/mL, AD after 4.1 years of follow-up 74.5 pg/mL; F = 6.04, $p = 0.003$). Thus, the average plasma Aβ42 levels were consistently elevated among those who subsequently developed AD compared with those who remained dementia-free.

We were able to obtain repeat blood samples in only 307 (58%) of the 530 individuals. This was due in part to mortality among 157 (29.6%) of the participants. Nonetheless, the correlation between the initial and subsequent plasma Aβ40 and Aβ42 levels was high (0.979 and 0.963, respectively). The change in overall mean Aβ40 levels differed slightly, but significantly, increasing over time (2.44 pg/mL; 95% CI 0.9 to 3.9). There was no significant change in

Aβ42 level over time (−0.009 pg/mL; 95% CI −0.83 to 0.82), but in comparison there were significant differences in plasma Aβ42 levels among the different groups over time. Among controls that remained dementia-free, the average difference over the 3 years was 0.25 pg/mL, for prevalent AD the difference was −0.75 pg/mL, whereas the difference among patients with incident AD was −3.02 pg/mL (F = 4.2, $p = 0.02$). This difference was significant. Thus, the average decline in plasma Aβ42 levels was 1.006 pg/mL/year in patients with newly acquired AD.

We found that baseline plasma Aβ40 and Aβ42 levels were significantly higher among those who died before the final assessment (table 3). Specifically, those individuals with AD who subsequently died had higher baseline Aβ42 levels than those individuals without AD, those with AD at

Table 2 *Rate ratio of AD by plasma Aβ42 levels as quartiles*

Quartiles of Aβ42, pg/mL	No. at risk	AD, no. (%)	RR (95% CI)*	RR (95% CI)†
≤36.97	124	19 (15.3)	1.0 ref.	1.0 ref.
36.97–60.2	116	19 (16.4)	1.3 (0.7–2.4)	1.1 (0.6–2.1)
60.2–84.15	102	21 (20.6)	1.9 (1.1–3.6)‡	1.9 (1.0–3.7)‡
≥84.15	109	27 (24.8)	2.4 (1.3–4.3)§	2.5 (1.3–4.8)§

Note that prevalent AD is omitted from this analysis of disease risk by baseline Aβ42 levels. The time-to-event was duration of follow-up from the baseline evaluation. All subjects were dementia-free at that time.

*Unadjusted.
†Adjusted for age, education, Aβ40 level, *APOE* genotype, and body mass index.
‡$P = 0.05$.
§$P < 0.006$.

AD = Alzheimer's disease; Aβ = amyloid β-peptide; RR = rate ratio.

Figure. Risk of Alzheimer's disease (AD) by quartiles of amyloid β-peptide (Aβ42) plasma levels at baseline. This graph depicts the cumulative proportion of individuals developing AD over the entire period of follow-up by the plasma Aβ42 level at the baseline or initial visit. Quartiles of plasma Aβ42 are identified as follows: filled circles = >84.15 pg/mL; triangles = 84.15 to 60.2 pg/mL; asterisks = 60.2 to 36.97 pg/mL; open circles = ≤36.97 pg/mL.

baseline, and patients who developed AD and survived. The analysis was repeated using multivariate analysis of covariance adjusting for age, BMI, and baseline plasma Aβ40 level, and the difference remained significant. Plasma Aβ40 levels did not differ significantly in those who survived with or without AD and those who did not in the multivariate analysis. The unadjusted analysis was repeated using log transformation of the values for plasma Aβ40 or the Aβ42 levels, and the differences remained statistically significant.

Discussion. Compared with elderly without AD, patients with AD and individuals who developed AD over the follow-up period had higher plasma Aβ40 and Aβ42 levels at the beginning of the study. Plasma Aβ40 and Aβ42 levels were also higher in

patients with AD at baseline compared with controls, though the differences were smaller. With use of the lowest quartile as the reference group, individuals in the upper two quartiles of plasma Aβ42 were at twice the risk of developing AD over the follow-up period. As a group, plasma levels of Aβ40 and Aβ42 drawn 3 years apart did not change significantly, but there was a significant decline in plasma Aβ42 levels in patients with newly acquired AD compared with those with prevalent AD or with controls. Over the study period, both plasma Aβ40 and Aβ42 levels were higher among those participants who died during the follow-up period than among those who survived. However, the multivariate analysis showed that baseline Aβ42 levels were higher in patients with recent onset of AD who died compared with those who survived with or without AD. This work extends our previous study, pointing out that differences in plasma level are related to age, BMI, and duration of time after the diagnosis. It also shows that the risk of AD may remain increased for those individuals with elevated plasma β42 over nearly 10 years.

Mutations in the genes that cause early-onset, familial forms of AD increase the extracellular concentration of Aβ42, which may augment Aβ deposition in the form of plaques in the brain.[35] This has led to the hypothesis that cerebral Aβ deposition is an essential early event in the pathogenesis of all forms of AD. Support for this hypothesis has come from the observation that plasma Aβ40 and Aβ42 levels were found to be higher in family members with mutations in presenilin 1 and the APP than among family members without the mutation.[8] We previously reported that plasma Aβ42, but not Aβ40, levels were increased among patients with incipient AD regardless of their *APOE* genotype in a small study from this same community.[6] Though patients with Down syndrome have higher plasma Aβ40 and Aβ42 levels due to the trisomy involving the region containing the APP,[36] even higher levels are found among pa-

Table 3 *Relation of plasma Aβ40 and Aβ42 levels, diagnosis, and vital status at last follow-up*

Group	Status*	No.	Age†	Aβ40, pg/mL	Aβ42, pg/mL
AD baseline	Alive	32	81.3 (7.5)	143.9 (40.6)	66.3 (23.6)
	Dead	45	84.6 (7.9)	160.4 (49.9)	70.3 (24.7)
Nondemented elderly	Alive	277	74.8 (5.6)	122.1 (39.7)‡	57.6 (33.7)
	Dead	88	77.4 (6.6)	168.3 (96.9)	62.8 (30.1)
AD follow-up	Alive	63	78.2 (5.6)	128.9 (45.8)	67.6 (49.8)§
	Dead	23	82.4 (8.1)	155.9 (45.0)	101.2 (77.1)

Comparisons are between participants who were alive or dead at the final assessment. Log-transformed values also differed significantly. Values in parentheses are SD.

*Status refers to the vital status at final assessment.

†Both nondemented elderly and patients with AD who died were significantly older than those surviving.

‡$P < 0.001$, comparing nondemented elderly follow-up alive vs dead.

§$P < 0.01$, comparing AD follow-up alive vs dead.

Aβ = amyloid β-peptide; AD = Alzheimer's disease.

tients who became demented.[12,37] It is not clear whether the *APOE* genotype influences plasma Aβ40 and Aβ42, because there are opposing reports.[12,37] Aβ40 and Aβ42 levels in plasma represent a heritable trait[9] that has been used as a phenotype in a genetic linkage analysis[10] that showed genetic linkage to markers on chromosome 10.

Do plasma Aβ42 levels represent a potential biological risk factor for AD? Our study has indicated that the answer to this question is complex. First, plasma Aβ40 and Aβ42 levels show some degree of overlap between elderly individuals who eventually develop AD and those who remained healthy, as would be expected with any risk factor. Second, we demonstrated that the measurement of plasma Aβ42 levels would need to be done at a point well before the onset of disease and thus could be used in the detection of individuals at higher-than-average risk. Careful inspection of the figure suggests that differences in frequency of AD by plasma Aβ42 levels emerge only after 2 to 3 years of follow-up. Therefore, a cross-sectional comparison of patients with established diagnoses of AD and control subjects would be unlikely to show a difference in the mean levels of either peptide. Third, the validity of plasma Aβ42 levels as a risk factor will be difficult to establish without more extensive longitudinal data because the highest levels were observed among individuals in the earliest stages of disease when the specificity of diagnosis is low. Therefore, high-risk individuals will need follow-up to a point at which the diagnostic specificity is greater. Although we observed little difference in the levels over a 3-year period, it may be necessary to complete repeated testing over a longer interval to examine changes in plasma levels with regard to disease course. Fourth, the highest Aβ40 and Aβ42 were found in those patients who died during the follow-up period, again implying that longitudinal, not cross-sectional, studies will be required to determine their usefulness in assessing disease risk. An alternative explanation is that the association with mortality implicates plasma Aβ40 and Aβ42 levels as indicators of prognosis.

We believe that neither plasma Aβ40 nor Aβ42 levels will be useful in the diagnosis of AD. Our limited results with repeated samples indicate that the plasma levels of Aβ42 begin to decrease soon after the diagnosis of AD has been established, which has been observed by others.[38] Exactly when plasma levels begin to decrease is uncertain. In contrast, CSF concentrations of Aβ42 have been used successfully when combined with other biochemical markers such as τ in the diagnosis of probable AD.[39,40] Aβ42 in the CSF is lower in patients with the disease than in controls. CSF concentrations of Aβ42 are increased early in the disease and decrease over time.[41] Previous studies examining the role of plasma Aβ40 and Aβ42 levels have shown little or no value in the diagnosis of AD.[5,42]

We found an inverse relation between Aβ40 levels

and cholesterol and HDL in plasma. There may well be a relationship between Aβ deposition in brain and cholesterol, but it has not been observed in plasma.[43,44] We could not identify an association between increased plasma Aβ and elevated serum cholesterol.[45] The studies of families with early-onset AD caused by mutations and the recent linkage of families with late-onset disease to chromosome 10 implicate exceptionally high plasma Aβ42 levels as part of the phenotype of a form of familial AD. Thus, an alternative possibility is that plasma Aβ42 may be increased only in a subset of individuals who develop AD. If the elevation in Aβ42 is a phenotypic marker in some, but not all, patients, then the search for the genes associated with higher levels will be extremely important because new metabolic pathways may be revealed. The persistence of the elevation in the patients studied here, the sparse number of individuals with elevated levels, and their death over the follow-up would suggest a moderately aggressive form of the disease that can be either genetic or environmental.

Aside from studies of early-onset familial AD,[46,47] there have been no reports suggesting that elevated levels of circulating plasma Aβ40 or Aβ42 are associated with mortality. It is intriguing to speculate that in some individuals with AD, higher levels of Aβ40 and Aβ42 may reflect a more advanced stage of disease or a more aggressive form of AD. The only animal model that has been studied is the senescence-accelerated mouse, which has a short life span and shows early signs of aging.[48] However, the amyloid deposition is systemic, affecting numerous systems in the body.

The source of Aβ40 and Aβ42 in plasma is unknown. Aβ is derived from proteolytic cleavage of the APP.[1] APP is produced by a variety of cell types in the brain and elsewhere, but the origins of Aβ brain deposits in AD and deposits in the cerebral vessels are uncertain. Amyloid deposits in cerebral vessels may be derived from circulating Aβ.[49] Some have suggested that the source of parenchymal cerebral amyloid deposits may originate in the periphery.[50] Platelets contain high levels of membrane-associated and soluble forms of APP, which, when cleaved, can release Aβ.[51-53] Platelets may also be the source of Aβ detected in whole blood[54] because Aβ, like APP, is also released upon platelet activation.[52,55] Aβ and APP formation and subsequent release from human platelets may be regulated by different multiple signal transduction mechanisms.[11] Knowledge of these mechanisms could provide a key to the pathogenesis of AD.

References

1. Selkoe DJ. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 1999;399:A23–A31.
2. Citron M, Vigo–Pelfrey C, Teplow DB, et al. Excessive production of amyloid beta-protein by peripheral cells of symptomatic and presymptomatic patients carrying the Swedish familial Alzheimer disease mutation. Proc Natl Acad Sci USA 1994;91:11993–11997.

3. Joachim CL, Mori H, Selkoe DJ. Amyloid beta-protein deposition in tissues other than brain in Alzheimer's disease. Nature 1989;341:226–230.
4. Vanderstichele H, Van Kerschaver E, Hesse C, et al. Standardization of measurement of beta-amyloid(1–42) in cerebrospinal fluid and plasma. Amyloid 2000;7:245–258.
5. Tamaoka A, Fukushima T, Sawamura N, et al. Amyloid beta protein in plasma from patients with sporadic Alzheimer's disease. J Neurol Sci 1996;141:65–68.
6. Mayeux R, Tang MX, Jacobs DM, et al. Plasma amyloid beta-peptide 1–42 and incipient Alzheimer's disease. Ann Neurol 1999;46:412–416.
7. Ghiso J, Calero M, Matsubara E, et al. Alzheimer's soluble amyloid beta is a normal component of human urine. FEBS Lett 1997;408:105–108.
8. Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 1996;2:864–870.
9. Ertekin–Taner N, Graff–Radford N, Younkin LH, et al. Heritability of plasma amyloid beta in typical late-onset Alzheimer's disease pedigrees. Genet Epidemiol 2001;21:19–30.
10. Ertekin–Taner N, Graff–Radford N, Younkin LH, et al. Linkage of plasma Abeta42 to a quantitative locus on chromosome 10 in late-onset Alzheimer's disease pedigrees. Science 2000;290:2303–2304.
11. Skovronsky DM, Lee VM, Pratico D. Amyloid precursor protein and amyloid beta peptide in human platelets. Role of cyclooxygenase and protein kinase C. J Biol Chem 2001;276:17036–17043.
12. Schupf N, Patel B, Silverman W, et al. Elevated plasma amyloid beta-peptide 1–42 and onset of dementia in adults with Down syndrome. Neurosci Lett 2001;301:199–203.
13. Tang MX, Stern Y, Marder K, et al. The APOE-epsilon4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics. JAMA 1998;279:751–755.
14. Pittman J, Andrews H, Tatemichi T, et al. Diagnosis of dementia in a heterogeneous population. A comparison of paradigm-based diagnosis and physician's diagnosis. Arch Neurol 1992;49:461–467.
15. Stern Y, Andrews H, Pittman J, et al. Diagnosis of dementia in a heterogeneous population. Development of a neuropsychological paradigm-based diagnosis of dementia and quantified correction for the effects of education. Arch Neurol 1992;49:453–460.
16. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–198.
17. Kaplan E, Goodglass H, Weintraub S. Boston Naming Test. Philadelphia: Lea & Febiger, 1983.
18. Benton A. FAS Test. In: Spreen O, Benton A, eds. Neurosensory Center Comprehensive Examination for Aphasia. Victoria, Canada: University of Victoria, 1967.
19. Goodglass H, Kaplan E. Assessment of aphasia and related disorders. Philadelphia: Lea & Febiger, 1983.
20. Weschler D. WAIS-R manual. New York: Psychological Corp., 1981.
21. Mattis S. Mental Status Examination for Organic Mental Syndrome in the Elderly Patient. New York: Grune & Stratton, 1976.
22. Rosen WG. The Rosen Drawing Test. Odessa, FL: Psychological Assessment Resources, 1981.
23. Benton AL. The Benton Visual Retention Test. New York: Psychological Corp., 1955.
24. Buschke H, Fuld PA. Evaluating storage, retention, and retrieval in disordered memory and learning. Neurology 1974;24:1019–1025.
25. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Press, 1994.
26. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939–944.
27. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry 1982;140:566–572.
28. US Census Bureau. Census of population and housing: summary tape file 1; technical documentation (available online).
29. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499–502.
30. Simons M, Keller P, Dichgans J, Schulz JB. Cholesterol and Alzheimer's disease: is there a link? Neurology 2001;57:1089–1093.
31. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990;31:545–548.
32. Maestre G, Ottman R, Stern Y, et al. Apolipoprotein E and Alzheimer's disease: ethnic variation in genotypic risks. Ann Neurol 1995;37:254–259.
33. Mehta PD, Pirttila T, Mehta SP, et al. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1–40 and 1–42 in Alzheimer disease. Arch Neurol 2000;57:100–105.
34. Potempska A, Mack K, Mehta P, Kim KS, Miller DL. Quantification of sub-femtomole amounts of Alzheimer amyloid beta peptides. Amyloid 1999;6:14–21.
35. Younkin SG. The role of A beta 42 in Alzheimer's disease. J Physiol Paris 1998;92:289–292.
36. Mehta PD, Dalton AJ, Mehta SP, et al. Increased plasma amyloid beta protein 1–42 levels in Down syndrome. Neurosci Lett 1998;241:13–16.
37. Cavani S, Tamaoka A, Moretti A, et al. Plasma levels of amyloid beta 40 and 42 are independent from ApoE genotype and mental retardation in Down syndrome. Am J Med Genet 2000;95:224–228.
38. Graff–Radford NR, Lucas JA, Younkin LH, Younkin SG. Longitudinal analysis of plasma Ab42 in subjects progressing from normal through mild cognitive impairment to Alzheimer's disease. Neurology 2003;60(suppl 1):A245.
39. Vanmechelen E, Vanderstichele H, Hulstaert F, et al. Cerebrospinal fluid tau and beta-amyloid(1–42) in dementia disorders. Mech Ageing Dev 2001;122:2005–2011.
40. Andreasen N, Minthon L, Davidsson P, et al. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 2001;58:373–379.
41. Kanai M, Matsubara E, Isoe K, et al. Longitudinal study of cerebrospinal fluid levels of tau, A beta1–40, and A beta1–42(43) in Alzheimer's disease: a study in Japan. Ann Neurol 1998;44:17–26.
42. Iwatsubo T. Amyloid beta protein in plasma as a diagnostic marker for Alzheimer's disease. Neurobiol Aging 1998;19:161–163.
43. Romas SN, Tang MX, Berglund L, Mayeux R. APOE genotype, plasma lipids, lipoproteins, and AD in community elderly. Neurology 1999;53:517–521.
44. Moroney JT, Tang MX, Berglund L, et al. Low-density lipoprotein cholesterol and the risk of dementia with stroke. JAMA 1999;282:254–260.
45. Smith CC, Hyatt PJ, Stanyer L, Betteridge DJ. Platelet secretion of beta-amyloid is increased in hypercholesterolaemia. Brain Res 2001;896:161–164.
46. Devi G, Fotiou A, Jyrinji D, et al. Novel presenilin 1 mutations associated with early onset of dementia in a family with both early-onset and late-onset Alzheimer disease. Arch Neurol 2000;57:1454–1457.
47. Wisniewski T, Dowjat WK, Buxbaum JD, et al. A novel Polish presenilin-1 mutation (P117L) is associated with familial Alzheimer's disease and leads to death as early as the age of 28 years. Neuroreport 1998;9:217–221.
48. Higuchi K, Wang J, Kitagawa K, et al. Accelerated senile amyloidosis induced by amyloidogenic Apoe-II gene shortens the life span of mice but does not accelerate the rate of senescence. J Gerontol 1996;51:B295–B302.
49. Chen M, Inestrosa NC, Ross GS, Fernandez HL. Platelets are the primary source of amyloid beta-peptide in human blood. Biochem Biophys Res Commun 1995;213:96–103.
50. DeMattos RB, Bales KR, Parsadanian M, et al. Plaque-associated disruption of CSF and plasma amyloid-beta (Abeta) equilibrium in a mouse model of Alzheimer's disease. J Neurochem 2002;81:229–236.
51. Van Nostrand WE, Schmaier AH, Farrow JS, Cunningham DD. Protease nexin-II (amyloid beta-protein precursor): a platelet alpha-granule protein. Science 1990;248:745–748.
52. Li QX, Whyte S, Tanner JE, et al. Secretion of Alzheimer's disease Abeta amyloid peptide by activated human platelets. Lab Invest 1998;78:461–469.
53. Cole GM, Galasko D, Shapiro IP, Saitoh T. Stimulated platelets release amyloid beta-protein precursor. Biochem Biophys Res Commun 1990;170:288–295.
54. Urmoneit B, Prikulis I, Wihl G, et al. Cerebrovascular smooth muscle cells internalize Alzheimer amyloid beta protein via a lipoprotein pathway: implications for cerebral amyloid angiopathy. Lab Invest 1997;77:157–166.
55. Smith CC. Stimulated release of the beta-amyloid protein of Alzheimer's disease by normal human platelets. Neurosci Lett 1997;235:157–159.

Neurology®

This information is current as of November 10, 2003

Updated Information & Services	including high resolution figures, can be found at: http://www.neurology.org/content/61/9/1185.full.html
References	This article cites 45 articles, 10 of which you can access for free at: http://www.neurology.org/content/61/9/1185.full.html##ref-list-1
Citations	This article has been cited by 21 HighWire-hosted articles: http://www.neurology.org/content/61/9/1185.full.html##otherarticles
Subspecialty Collections	This article, along with others on similar topics, appears in the following collection(s): **All epidemiology** http://www.neurology.org//cgi/collection/all_epidemiology **Alzheimer's disease** http://www.neurology.org//cgi/collection/alzheimers_disease **Risk factors in epidemiology** http://www.neurology.org//cgi/collection/risk_factors_in_epidemiology
Permissions & Licensing	Information about reproducing this article in parts (figures,tables) or in its entirety can be found online at: http://www.neurology.org/misc/about.xhtml#permissions
Reprints	Information about ordering reprints can be found online: http://www.neurology.org/misc/addir.xhtml#reprintsus

AMERICAN ACADEMY OF
NEUROLOGY®